Advertisement

Association of single nucleotide polymorphism in hsa-miR-499 and hsa-miR-196a2 with the risk of prostate cancer

  • Ramin Nouri
  • Saeid GhorbianEmail author
Urology - Original Paper
  • 22 Downloads

Abstract

Background

Prostate cancer (PCa) is one the most common malignant cancers in men. Micro-RNAs are a group of a noncoding small molecule, which plays critical roles in signalling pathways, metabolism, apoptosis and cancer development. The purpose of this study was to examine the possible association between the hsa-miR-499 (rs3746444) and hsa-miR-196a2 (rs11614913) gene polymorphisms with the risk of PCa.

Methods

The case–control investigation was performed on 300 peripheral blood samples, consisting of 150 patients with PCa and 150 healthy men without a family history of cancers. Genetic variations of hsa-miR-499 and hsa-miR-196a2 genes were assessed using the PCR–RFLP method.

Results

The T/T + TC/CC genotype frequencies showed a significant association between has-mir499 (rs3746444 T>C) gene polymorphism with the risk of PCa (p = 0.027; OR 1.780; 95% CI 1.030–3.113). The genotype frequencies of hsa-miR-196a2 gene did not reveal a statistically significant difference between two groups (p > 0.05).

Conclusion

Our findings supported that hsa-miR-499 gene polymorphism significantly increased susceptibility to PCa and may be considered as a potential prognostic biomarker in PCa patients. The findings suggested that no correlation between hsa-miR-196a2 gene polymorphism and PCa susceptibility in an Iranian population.

Keywords

Prostate cancer Prognostic biomarker Hsa-miR-499 Hsa-miR-196a 

Notes

Acknowledgements

This article was extracted from an MSc thesis (IR. 951010) at Ahar Branch Islamic Azad University. We would like to appreciate all the staffs of Imam Khomeini Hospital and medical University of Tehran.

Compliance with ethical standards

Conflict of interest

Ramin Nouri and Saeid Ghorbian declare that no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Jaiswal S, Sarmad R, Arora S, Dasaraju R, Sarmad K (2015) Prostate cancer for the internist. N Am J Med Sci 7(10):429–435CrossRefGoogle Scholar
  2. 2.
    Gavin AT, Donnelly D, Donnelly C, Drummond FJ, Morgan E, Gormley GJ et al (2016) Effect of investigation intensity and treatment differences on prostate cancer survivor’s physical symptoms, psychological well-being and health-related quality of life: a two country cross-sectional study. BMJ Open 6(12):e012952CrossRefGoogle Scholar
  3. 3.
    Aaron L, Franco O, Hayward SW (2016) Review of prostate anatomy and embryology and the etiology of BPH. Urol Clin N Am 43(3):279–288CrossRefGoogle Scholar
  4. 4.
    Rennert H, Zeigler-Johnson CM, Addya K, Finley MJ, Walker AH, Spangler E et al (2005) Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomark Prev 14(4):949–957CrossRefGoogle Scholar
  5. 5.
    Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL et al (2009) Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomark Prev 18(6):1869–1880CrossRefGoogle Scholar
  6. 6.
    Kian R, Moradi S, Ghorbian S (2018) Role of components of microRNA machinery in carcinogenesis. Exp Oncol 40(1):2–9Google Scholar
  7. 7.
    Chen C, Zhang Y, Zhang L, Weakley SM, Yao Q (2011) MicroRNA-196: critical roles and clinical applications in development and cancer. J Cell Mol Med 15(1):14–23CrossRefGoogle Scholar
  8. 8.
    Kawasaki H, Taira K (2004) MicroRNA-196 inhibits HOXB8 expression in myeloid differentiation of HL60 cells. Nucleic Acids Symp Ser 2004(48):211–212CrossRefGoogle Scholar
  9. 9.
    Fazli M, Ghorbian S (2018) Association study of non-coding RNA miR-499 and miR196a2 gene polymorphisms with the risk of idiopathic recurrent pregnancy loss. Gene Cell Tissue 5(1):e67253Google Scholar
  10. 10.
    Jeon YJ, Kim OJ, Kim SY (2013) Association of the miR-146a, miR-149, miR-196a2, and miR-499 polymorphisms with ischemic stroke and silent brain infarction risk. Arterioscler ThrombVasc Biol 33:420–430CrossRefGoogle Scholar
  11. 11.
    Ahn DH, Rah H, Choi YK, Jeon YJ, Min KT, Kwack K et al. (2013) Association of the miR-146aCNG, miR-149 TNC, miR-196a2TNC, and miR-499ANG polymorphisms with gastric cancer risk and survival in the Korean population. Mol Carcinog 52(Suppl.1):E39–E51CrossRefGoogle Scholar
  12. 12.
    Forstner AJ, Hofmann A, Maaser A, Sumer S, Khudayberdiev S, Mühleisen TW et al (2015) Genome-wide analysis implicates microRNAs and their target genes in the development of bipolar disorder. Transl Psychiatry 5(11):e678CrossRefGoogle Scholar
  13. 13.
    Chen C, Yang S, Chaugai S, Wang Y, Wang DW (2014) Meta-analysis of Hsa-mir-499 polymorphism (rs3746444) for cancer risk: evidence from 31 case-control studies. BMC Med Genet 15:126CrossRefGoogle Scholar
  14. 14.
    Ryan BM, Robles AI, Harris CC (2010) Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 10(6):389–402CrossRefGoogle Scholar
  15. 15.
    He B, Pan Y, Cho WC, Xu Y, Gu L, Nie Z et al (2012) The association between four genetic variants in microRNAs (rs11614913, rs2910164, rs3746444, rs2292832) and cancer risk: evidence from published studies. PLoSONE 7(11):e49032CrossRefGoogle Scholar
  16. 16.
    Qiu MT, Hu JW, Ding XX, Yang X, Zhang Z, Yin R, Xu L (2012) Hsa-miR-499 rs3746444 polymorphism contributes to cancer risk: a meta-analysis of 12 studies. PLoSONE 7(12):e50887CrossRefGoogle Scholar
  17. 17.
    Nikolic Z, Savic Pavicevic D, Vucic N, Cidilko S, Filipovic N, Cerovic S et al (2015) Assessment of association between genetic variants in microRNA genes hsa-miR-499, hsa-miR-196a2 and hsa-miR-27a and prostate cancer risk in Serbian population. Exp Mol Pathol 99(1):145–150CrossRefGoogle Scholar
  18. 18.
    Hashemi M, Moradi N, Ziaee SAM, Narouie B, Soltani MH, Rezaei M et al (2016) Association between single nucleotide polymorphism in miR-499, miR-196a2, miR-146a and miR-149 and prostate cancer risk in a sample of Iranian population. J Adv Res 7(3):491–498CrossRefGoogle Scholar
  19. 19.
    Greco F, Inferrera A, La Rocca R, Navarra M, Casciaro M, Grosso G et al (2018) The potential role of MicroRNAs as biomarkers in benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol Focus 4569(18):30009–30009Google Scholar
  20. 20.
    Mi Y, Ren K, Zou J, Bai Y, Zhang L, Zuo L et al (2018) The association between three genetic variants in MicroRNAs (Rs11614913, Rs2910164, Rs3746444) and prostate cancer risk. Cell Physiol Biochem 48(1):149–157CrossRefGoogle Scholar
  21. 21.
    Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215CrossRefGoogle Scholar
  22. 22.
    Wang H, Peng R, Wang J, Qin Z, Xue L (2018) Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin Epigenet 10(1):59CrossRefGoogle Scholar
  23. 23.
    Ni J, Bucci J, Chang L, Malouf D, Graham P, Li Y (2017) Targeting MicroRNAs in prostate cancer radiotherapy. Theranostics 7(13):3243–3259CrossRefGoogle Scholar
  24. 24.
    George GP, Gangwar R, Mandal RK, Sankhwar SN, Mittal RD (2011) Genetic variation in microRNA genes and prostate cancer risk in North Indian population. Mol Biol Rep 38(3):1609–1615CrossRefGoogle Scholar
  25. 25.
    Hashemi M, Moradi N, Ziaee SA, Narouie B, Soltani MH, Rezaei M et al (2016) Association between single nucleotide polymorphism in miR-499, miR-196a2, miR-146a and miR-149 and prostate cancer risk in a sample of Iranian population. J Adv Res 7(3):491–498CrossRefGoogle Scholar
  26. 26.
    Yan W, Gao X, Zhang S (2017) Association of miR-196a2 rs11614913 and miR-499 rs3746444 polymorphisms with cancer risk: a meta-analysis. Oncotarget 8(69):114344–114359CrossRefGoogle Scholar
  27. 27.
    Parlayan C, Ikeda S, Sato N, Sawabe M, Muramatsu M, Arai T (2014) Association analysis of single nucleotide polymorphisms in miR-146a and miR-196a2 on the prevalence of cancer in elderly Japanese: a case-control study. Asian Pac J Cancer Prev APJCP 15(5):2101–2107CrossRefGoogle Scholar
  28. 28.
    Dai ZM, Kang HF, Zhang WG, Li HB, Zhang SQ, Ma XB et al (2016) The associations of single nucleotide polymorphisms in miR196a2, miR-499, and miR-608 with breast cancer susceptibility: a STROBE-compliant observational study. Medicine (Baltimore) 95(7):e2826CrossRefGoogle Scholar
  29. 29.
    Zhang B, Pan X, Cobb GP, Anderson TA (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302(1):1–12CrossRefGoogle Scholar
  30. 30.
    Li X, Wang J, Jia Z, Cui Q, Zhang C, Wang W et al (2013) MiR-499 regulates cell proliferation and apoptosis during late-stage cardiac differentiation via Sox6 and cyclin D1. PLoSONE 8(9):e74504CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Molecular Genetics, Ahar BranchIslamic Azad UniversityAharIran

Personalised recommendations